✦ LIBER ✦

Residential mobility and long-term treatment of Hypertension

✍ Scribed by Linda Cowan; Roger Detels; Marilyn Farber; Eun Sul Lee; Gail McCray; Sheila O'Flynn; Mary Jo Parnell

Publisher: Springer US
Year: 1980
Tongue: English
Weight: 476 KB
Volume: 5
Category: Article
ISSN: 0094-5145
DOI: 10.1007/bf01323988

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term pharmacologic treatment of wom

Long-term pharmacologic treatment of women with hypertension

✍ Pamela Charney 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB

## Abstract As reviewed in “Hypertension in Women: What is Really Known?” (Women's Caucus Working Group on Women's Health of the Society of General Internal Medicine [1991] Ann Intern Med __115__:287–293), the published literature reveals that hypertension frequently occurs in women and that only s

The efficacy and tolerability of long-te

The efficacy and tolerability of long-term felodipine treatment in hypertension

✍ H. Borgmästars; B. Forsén; J. Tuomilehto; R. Hellebø; P. O. Walle; H. M. Nielsen 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 612 KB

Withdrawal of guanfacine after long-term

Withdrawal of guanfacine after long-term treatment in essential hypertension

✍ C. Zamboulis; J. L. Reid 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 529 KB

Long-term follow-up of portopulmonary hy

Long-term follow-up of portopulmonary hypertension: Effect of treatment with epoprostenol

✍ Oren K. Fix; Nathan M. Bass; Teresa De Marco; Raphael B. Merriman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Moderate to severe portopulmonary hypertension (PPHTN) increases the risks of orthotopic liver transplantation (OLT). Epoprostenol is an effective treatment of PPHTN, but long-term effects on pulmonary hemodynamics or liver function in PPHTN are poorly defined. We sought to describe the long-term ef

Residential versus day treatment for chi

Residential versus day treatment for children: A long-term follow-up study

✍ Gerard J. Erker; H. Russell Searight; Ebraham Amanat; Pamela D. White 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 519 KB

Long-term octreotide treatment prevents

Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats

✍ C C Sieber; F Lee; R J Groszmann 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

Chronically portal-hypertensive rats show in vitro vascular hyporeactivity in large part mediated by the endothelium-derived vasodilator nitric oxide. We tested whether long-term octreotide treatment (15 micrograms/kg subcutaneously in 5% D/W, 8-hourly) corrects the in vitro vascular hyporeactivity.